Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Fentanyl ETHYPHARM for Breakthrough Pain in Opioid-treated Patients With Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~1. Written informed consent~2. Malignant solid tumor or a hematological malignancy causing cancer-related pain~3. Background opioid treatment at a stable dose for at least a week~4. One to four episodes of breakthrough pain per day~Main exclusion criteria:~1. Hypersensitivity to fentanyl or to any of the excipients~2. Intrathecal opioids~3. Recent history of substance abuse~4. Recent or planned therapy that would alter pain~5. Moderate or severe hepatic or renal disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fentanyl / Placebo (Type: EXPERIMENTAL): After an open-label titration to identify an optimal dose, patients were randomized to 1 of 13 prespecified sequences of 9 tablets (6 fentanyl and 3 placebo)

Based on this trial design, predict the completion outcome and termination type (if applicable).